{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Capsule%2FTablet%29",
    "query": {
      "intervention": "Placebo (Capsule/Tablet)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 677,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Capsule%2FTablet%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-21T21:54:15.135Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04372121",
      "title": "Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Add-back capsule (E2 1 mg / NETA 0.5 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule to match Add-back capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kissei Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2020-03-23",
      "completion_date": "2021-02-16",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-09-21T21:54:15.135Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Norwalk",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04372121"
    },
    {
      "nct_id": "NCT04056195",
      "title": "Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "SKI-O-703",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oscotec Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2019-10-11",
      "completion_date": "2023-01-10",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-09-21T21:54:15.135Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Durham, North Carolina • Greenville, North Carolina + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04056195"
    },
    {
      "nct_id": "NCT06248229",
      "title": "A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fatigue",
        "Attention Deficit Hyperactivity Disorder",
        "Attention Deficit Disorder"
      ],
      "interventions": [
        {
          "name": "Dyanavel XR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rochester Center for Behavioral Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-09-01",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-09-21T21:54:15.135Z",
      "location_count": 1,
      "location_summary": "Rochester Hills, Michigan",
      "locations": [
        {
          "city": "Rochester Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06248229"
    },
    {
      "nct_id": "NCT01530022",
      "title": "Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lacosamide (LCM)",
          "type": "DRUG"
        },
        {
          "name": "Carbamazepine Immediate Release (CBZ-IR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2012-05",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-01-24",
      "last_synced_at": "2026-09-21T21:54:15.135Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Overland Park, Kansas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01530022"
    },
    {
      "nct_id": "NCT03467763",
      "title": "Trial of an Intervention to Improve Metformin Persistence and Adherence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Metformin Adverse Reaction",
        "Tolerance"
      ],
      "interventions": [
        {
          "name": "Metformin Extended Release Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 13,
      "start_date": "2018-02-09",
      "completion_date": "2020-08-01",
      "has_results": true,
      "last_update_posted_date": "2020-12-07",
      "last_synced_at": "2026-09-21T21:54:15.135Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03467763"
    },
    {
      "nct_id": "NCT01755455",
      "title": "Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Anemia, Iron-Deficiency"
      ],
      "interventions": [
        {
          "name": "Ferrous sulfate 325mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 22,
      "start_date": "2011-06",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-03-16",
      "last_synced_at": "2026-09-21T21:54:15.135Z",
      "location_count": 2,
      "location_summary": "Portland, Maine • Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Portland",
          "state": "Maine"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01755455"
    },
    {
      "nct_id": "NCT03337308",
      "title": "A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemias"
      ],
      "interventions": [
        {
          "name": "Bempedoic Acid + Ezetimibe Fixed-Dose Combination",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Bempedoic Acid",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Esperion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 382,
      "start_date": "2017-10-23",
      "completion_date": "2018-07-18",
      "has_results": true,
      "last_update_posted_date": "2020-04-08",
      "last_synced_at": "2026-09-21T21:54:15.135Z",
      "location_count": 5,
      "location_summary": "Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more",
      "locations": [
        {
          "city": "Ames",
          "state": "Iowa"
        },
        {
          "city": "Nashua",
          "state": "New Hampshire"
        },
        {
          "city": "Statesville",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03337308"
    },
    {
      "nct_id": "NCT01038609",
      "title": "Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Hydrocodone/Acetaminophen Extended Release",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Morphine Extended Release",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 250,
      "start_date": "2009-12",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2014-04-08",
      "last_synced_at": "2026-09-21T21:54:15.135Z",
      "location_count": 4,
      "location_summary": "Peoria, Arizona • Austin, Texas • San Marcos, Texas + 1 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Marcos",
          "state": "Texas"
        },
        {
          "city": "West Jordan",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01038609"
    },
    {
      "nct_id": "NCT03204318",
      "title": "SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis Related Pain"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate placebo",
          "type": "DRUG"
        },
        {
          "name": "Relugolix placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 638,
      "start_date": "2017-12-07",
      "completion_date": "2021-04-08",
      "has_results": false,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-09-21T21:54:15.135Z",
      "location_count": 43,
      "location_summary": "Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03204318"
    },
    {
      "nct_id": "NCT03129542",
      "title": "Midodrine Hydrochloride in Early Sepsis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sepsis",
        "Blood Pressure"
      ],
      "interventions": [
        {
          "name": "Midodrine Hydrochloride 10 milligrams",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2017-08-30",
      "completion_date": "2020-05-15",
      "has_results": false,
      "last_update_posted_date": "2021-02-05",
      "last_synced_at": "2026-09-21T21:54:15.135Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03129542"
    }
  ]
}